Beehive_BKK的个人主页 - 老虎社区

Beehive_BKK

Beehive_BKK

暂无个人介绍

IP属地：未知

3关注

1粉丝

0主题

0勋章

2021-04-29

เซม

@DWP:$HUMBL Inc.(HMBL)$bleeeeeeding 😪

2021-03-15

🙏🏻

Better Buy: NIO vs. XPeng Motors<blockquote>更值得购买：蔚来与小鹏汽车</blockquote>

2021-03-04

Hmmmmm

抱歉，原内容已删除

2021-03-04

👌🏻

Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴Bharat Biotech COVID-19候选疫苗显示出81%的功效后，Ocugen股价飙升</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3576882204250083","uuid":"3576882204250083","gmtCreate":1613788868700,"gmtModify":1613789950950,"name":"Beehive_BKK","pinyin":"beehivebkkbeehivebkk","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":109695483,"gmtCreate":1619688398542,"gmtModify":1634210712908,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"เซม","listText":"เซม","text":"เซม","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/109695483","repostId":"374290611","repostType":1,"repost":{"id":374290611,"gmtCreate":1619447027033,"gmtModify":1631888271015,"author":{"id":"3574652001822174","authorId":"3574652001822174","name":"DWP","avatar":"https://static.tigerbbs.com/cf842b9e680a5ecebea8472f4a157226","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574652001822174","authorIdStr":"3574652001822174"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","listText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","text":"$HUMBL Inc.(HMBL)$bleeeeeeding 😪","images":[{"img":"https://static.tigerbbs.com/8b79a88da903c7e0e8036cad05a222bf","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374290611","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1721,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322112539,"gmtCreate":1615782451321,"gmtModify":1703492874861,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"🙏🏻","listText":"🙏🏻","text":"🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322112539","repostId":"1161179297","repostType":4,"repost":{"id":"1161179297","kind":"news","pubTimestamp":1615771321,"share":"https://www.laohu8.com/m/news/1161179297?lang=zh_CN&edition=full","pubTime":"2021-03-15 09:22","market":"us","language":"en","title":"Better Buy: NIO vs. XPeng Motors<blockquote>更值得购买：蔚来与小鹏汽车</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161179297","media":"Motley Fool","summary":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.Stocks of electric-vehicle  makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach","content":"<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p><p><blockquote>即使在股价低迷之后，这两家中国电动汽车制造商的估值也很高。</blockquote></p><p> Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p><p><blockquote>电动汽车(EV)制造商的股票在2020年加速上涨。众所周知，中国电动汽车股票是最受欢迎的股票之一，因为这个全球最大的汽车市场继续向交通领域的电气化迈进。</blockquote></p><p> EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p><p><blockquote>2020年，中国电动汽车销量超过100万辆，政府希望到2025年将这一数字增长到500万辆。据研究机构BloombergNEF称，到2030年，这一数字可能达到1000万，到2040年接近2000万。两家希望利用这一扩张的电动汽车制造商是<b>蔚来</b>（纽约证券交易所代码：蔚来）和<b>小鹏</b>（纽约证券交易所代码：XPEV）。投资者可能想知道哪一个更好，尤其是在该行业股价出现调整之后。</blockquote></p><p> <b>The right market</b></p><p><blockquote><b>合适的市场</b></blockquote></p><p> As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p><p><blockquote>如上所述，世界上最大的汽车市场具有巨大的增长潜力。问题是，将会有很多公司寻求资本化。<b>特斯拉</b>（纳斯达克：TSLA）在上海建立第二家制造工厂是有原因的。尽管蔚来和小鹏汽车可能是中国最知名的电动汽车制造商，但它们总共交付了131,000辆纯电动汽车的一半多一点。<b>比亚迪</b>（场外交易代码：比亚迪）2020年售出。</blockquote></p><p> NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p><p><blockquote>蔚来在2020年交付了近44,000辆汽车，而小鹏汽车的销量比2019年增加了一倍多，达到27,041辆。两家公司最近都推出了轿车车型，都希望这些车型能够成为未来销售增长的重要推动力。</blockquote></p><p> XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p><p><blockquote>自2020年初推出以来，小鹏汽车的P7运动型轿车累计交付量已超过20,000辆，超越G3紧凑型SUV成为该公司最受欢迎的汽车。这标志着中国电动汽车初创企业交付20,000辆汽车的最快速度。</blockquote></p><p> NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p><p><blockquote>蔚来今年早些时候推出了新款ET7豪华轿车。ET7将于明年初上市，具有一些复杂的功能。时尚的外观包括自动驾驶传感器、“水晶般的心跳”尾灯、全玻璃车顶和数字进入系统，该系统可以延伸齐平把手，并在驾驶员靠近时自动释放车门的“电子锁”。</blockquote></p><p> <b>Priced for perfection</b></p><p><blockquote><b>完美定价</b></blockquote></p><p> The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p><p><blockquote>强劲的销售增长以及中国电动汽车的巨大潜力已经让投资者涌入这些股票。但在蔚来和小鹏汽车的股价去年飙升后，这些股票分别较2021年1月的高点下跌了27%和38%，现在是看看哪一个可能更好买入的好时机。</blockquote></p><p> Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p><p><blockquote>两家公司都尚未盈利，因此衡量估值的一种方法是使用销售额而不是收益。市销率（P/S）都非常高，但销售额预计将快速增长，这是比较两家公司的相关指标。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的蔚来市值数据</span></p></blockquote></p><p> Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p><p><blockquote>尽管蔚来的市值较高，但以市盈率衡量，它的成本低于小鹏汽车。蔚来还通过其电池更换计划对市场采取了独特的方法，允许客户通过更快的电池更换来“充电”。该公司表示，其自动电池交换站只需三分钟即可更换充满电的电池。</blockquote></p><p> <b>Looking ahead</b></p><p><blockquote><b>展望未来</b></blockquote></p><p> NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p><p><blockquote>蔚来凭借ET7进军豪华轿车领域可能有助于将该公司推向一个新的水平。2020年毛利率、毛利润和经营现金流均为正，表明盈利之路在望。</blockquote></p><p> Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p><p><blockquote>两家公司都希望有足够的资本来资助计划的增长工作。截至2020年12月31日，蔚来资产负债表上的现金和现金等价物、限制性现金和短期投资为65亿美元，小鹏汽车约为54亿美元。两家公司可以通过在香港联交所上市来筹集更多资金，据报道，两家公司都在考虑上市。</blockquote></p><p> For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p><p><blockquote>对于只想选择一家公司来参与中国电动汽车增长的投资者来说，蔚来似乎是这两家公司中更好的选择。任何投资仍然属于投资组合的投机部分，有可能出现很大的波动。但对于那些能够承受这一点并进行适当投资的人来说，最近股价的下跌使蔚来目前比小鹏汽车更值得买入。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Buy: NIO vs. XPeng Motors<blockquote>更值得购买：蔚来与小鹏汽车</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Buy: NIO vs. XPeng Motors<blockquote>更值得购买：蔚来与小鹏汽车</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-03-15 09:22</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p><p><blockquote>即使在股价低迷之后，这两家中国电动汽车制造商的估值也很高。</blockquote></p><p> Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p><p><blockquote>电动汽车(EV)制造商的股票在2020年加速上涨。众所周知，中国电动汽车股票是最受欢迎的股票之一，因为这个全球最大的汽车市场继续向交通领域的电气化迈进。</blockquote></p><p> EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p><p><blockquote>2020年，中国电动汽车销量超过100万辆，政府希望到2025年将这一数字增长到500万辆。据研究机构BloombergNEF称，到2030年，这一数字可能达到1000万，到2040年接近2000万。两家希望利用这一扩张的电动汽车制造商是<b>蔚来</b>（纽约证券交易所代码：蔚来）和<b>小鹏</b>（纽约证券交易所代码：XPEV）。投资者可能想知道哪一个更好，尤其是在该行业股价出现调整之后。</blockquote></p><p> <b>The right market</b></p><p><blockquote><b>合适的市场</b></blockquote></p><p> As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p><p><blockquote>如上所述，世界上最大的汽车市场具有巨大的增长潜力。问题是，将会有很多公司寻求资本化。<b>特斯拉</b>（纳斯达克：TSLA）在上海建立第二家制造工厂是有原因的。尽管蔚来和小鹏汽车可能是中国最知名的电动汽车制造商，但它们总共交付了131,000辆纯电动汽车的一半多一点。<b>比亚迪</b>（场外交易代码：比亚迪）2020年售出。</blockquote></p><p> NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p><p><blockquote>蔚来在2020年交付了近44,000辆汽车，而小鹏汽车的销量比2019年增加了一倍多，达到27,041辆。两家公司最近都推出了轿车车型，都希望这些车型能够成为未来销售增长的重要推动力。</blockquote></p><p> XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p><p><blockquote>自2020年初推出以来，小鹏汽车的P7运动型轿车累计交付量已超过20,000辆，超越G3紧凑型SUV成为该公司最受欢迎的汽车。这标志着中国电动汽车初创企业交付20,000辆汽车的最快速度。</blockquote></p><p> NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p><p><blockquote>蔚来今年早些时候推出了新款ET7豪华轿车。ET7将于明年初上市，具有一些复杂的功能。时尚的外观包括自动驾驶传感器、“水晶般的心跳”尾灯、全玻璃车顶和数字进入系统，该系统可以延伸齐平把手，并在驾驶员靠近时自动释放车门的“电子锁”。</blockquote></p><p> <b>Priced for perfection</b></p><p><blockquote><b>完美定价</b></blockquote></p><p> The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p><p><blockquote>强劲的销售增长以及中国电动汽车的巨大潜力已经让投资者涌入这些股票。但在蔚来和小鹏汽车的股价去年飙升后，这些股票分别较2021年1月的高点下跌了27%和38%，现在是看看哪一个可能更好买入的好时机。</blockquote></p><p> Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p><p><blockquote>两家公司都尚未盈利，因此衡量估值的一种方法是使用销售额而不是收益。市销率（P/S）都非常高，但销售额预计将快速增长，这是比较两家公司的相关指标。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的蔚来市值数据</span></p></blockquote></p><p> Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p><p><blockquote>尽管蔚来的市值较高，但以市盈率衡量，它的成本低于小鹏汽车。蔚来还通过其电池更换计划对市场采取了独特的方法，允许客户通过更快的电池更换来“充电”。该公司表示，其自动电池交换站只需三分钟即可更换充满电的电池。</blockquote></p><p> <b>Looking ahead</b></p><p><blockquote><b>展望未来</b></blockquote></p><p> NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p><p><blockquote>蔚来凭借ET7进军豪华轿车领域可能有助于将该公司推向一个新的水平。2020年毛利率、毛利润和经营现金流均为正，表明盈利之路在望。</blockquote></p><p> Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p><p><blockquote>两家公司都希望有足够的资本来资助计划的增长工作。截至2020年12月31日，蔚来资产负债表上的现金和现金等价物、限制性现金和短期投资为65亿美元，小鹏汽车约为54亿美元。两家公司可以通过在香港联交所上市来筹集更多资金，据报道，两家公司都在考虑上市。</blockquote></p><p> For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p><p><blockquote>对于只想选择一家公司来参与中国电动汽车增长的投资者来说，蔚来似乎是这两家公司中更好的选择。任何投资仍然属于投资组合的投机部分，有可能出现很大的波动。但对于那些能够承受这一点并进行适当投资的人来说，最近股价的下跌使蔚来目前比小鹏汽车更值得买入。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","NIO":"蔚来"},"source_url":"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161179297","content_text":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.\nStocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.\nEV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are NIO (NYSE:NIO) and XPeng (NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.\nThe right market\nAs noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.Tesla (NASDAQ:TSLA) built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that BYD (OTC:BYDDY) sold in 2020.\nNIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.\nXPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.\nNIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.\nPriced for perfection\nThe strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.\nNeither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The price-to-sales ratios (P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.\nNIO MARKET CAP DATA BY YCHARTS\nThough NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.\nLooking ahead\nNIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.\nBoth companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.\nFor investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.","news_type":1,"symbols_score_info":{"XPEV":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":1373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364880038,"gmtCreate":1614833458024,"gmtModify":1703481731661,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"Hmmmmm","listText":"Hmmmmm","text":"Hmmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/364880038","repostId":"2116152999","repostType":4,"isVote":1,"tweetType":1,"viewCount":1311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364834174,"gmtCreate":1614832110998,"gmtModify":1703481713436,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"👌🏻","listText":"👌🏻","text":"👌🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/364834174","repostId":"1172714394","repostType":4,"repost":{"id":"1172714394","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614783206,"share":"https://www.laohu8.com/m/news/1172714394?lang=zh_CN&edition=full","pubTime":"2021-03-03 22:53","market":"us","language":"en","title":"Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴Bharat Biotech COVID-19候选疫苗显示出81%的功效后，Ocugen股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172714394","media":"老虎资讯综合","summary":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-develo","content":"<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>飙升41.0%，此前该生物制药公司表示，其共同开发合作伙伴Bharat Biotech发布了对其COVID-19候选疫苗科瓦克辛的3期试验的中期分析，该试验显示疗效为81%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat在印度的3期试验招募了25800名年龄在18至91岁的参与者，首次中期分析基于43例病例。对安全性数据库的审查显示，严重、严重和医疗护理的不良事件发生率较低，并且在疫苗组和安慰剂组之间保持平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen首席执行官Shankar Musunuri表示：“这些结果部分表明针对快速出现的英国变种具有显着的免疫原性，这代表着朝着概述EUA和美国批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于整个病毒体的候选疫苗，旨在满足我们国家针对COVID-19的疫苗库中尚未满足的重大需求。”Ocugen的股价在过去三个月内飙升了3,071.5%，而iShares纳斯达克生物技术ETF上涨了6.8%，标普500上涨了5.6%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴Bharat Biotech COVID-19候选疫苗显示出81%的功效后，Ocugen股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴Bharat Biotech COVID-19候选疫苗显示出81%的功效后，Ocugen股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-03 22:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>飙升41.0%，此前该生物制药公司表示，其共同开发合作伙伴Bharat Biotech发布了对其COVID-19候选疫苗科瓦克辛的3期试验的中期分析，该试验显示疗效为81%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat在印度的3期试验招募了25800名年龄在18至91岁的参与者，首次中期分析基于43例病例。对安全性数据库的审查显示，严重、严重和医疗护理的不良事件发生率较低，并且在疫苗组和安慰剂组之间保持平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen首席执行官Shankar Musunuri表示：“这些结果部分表明针对快速出现的英国变种具有显着的免疫原性，这代表着朝着概述EUA和美国批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于整个病毒体的候选疫苗，旨在满足我们国家针对COVID-19的疫苗库中尚未满足的重大需求。”Ocugen的股价在过去三个月内飙升了3,071.5%，而iShares纳斯达克生物技术ETF上涨了6.8%，标普500上涨了5.6%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172714394","content_text":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":364880038,"gmtCreate":1614833458024,"gmtModify":1703481731661,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576882204250083","idStr":"3576882204250083"},"themes":[],"htmlText":"Hmmmmm","listText":"Hmmmmm","text":"Hmmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/364880038","repostId":"2116152999","repostType":4,"isVote":1,"tweetType":1,"viewCount":1311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322112539,"gmtCreate":1615782451321,"gmtModify":1703492874861,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576882204250083","idStr":"3576882204250083"},"themes":[],"htmlText":"🙏🏻","listText":"🙏🏻","text":"🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322112539","repostId":"1161179297","repostType":4,"repost":{"id":"1161179297","kind":"news","pubTimestamp":1615771321,"share":"https://www.laohu8.com/m/news/1161179297?lang=zh_CN&edition=full","pubTime":"2021-03-15 09:22","market":"us","language":"en","title":"Better Buy: NIO vs. XPeng Motors<blockquote>更值得购买：蔚来与小鹏汽车</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161179297","media":"Motley Fool","summary":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.Stocks of electric-vehicle  makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach","content":"<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p><p><blockquote>即使在股价低迷之后，这两家中国电动汽车制造商的估值也很高。</blockquote></p><p> Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p><p><blockquote>电动汽车(EV)制造商的股票在2020年加速上涨。众所周知，中国电动汽车股票是最受欢迎的股票之一，因为这个全球最大的汽车市场继续向交通领域的电气化迈进。</blockquote></p><p> EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p><p><blockquote>2020年，中国电动汽车销量超过100万辆，政府希望到2025年将这一数字增长到500万辆。据研究机构BloombergNEF称，到2030年，这一数字可能达到1000万，到2040年接近2000万。两家希望利用这一扩张的电动汽车制造商是<b>蔚来</b>（纽约证券交易所代码：蔚来）和<b>小鹏</b>（纽约证券交易所代码：XPEV）。投资者可能想知道哪一个更好，尤其是在该行业股价出现调整之后。</blockquote></p><p> <b>The right market</b></p><p><blockquote><b>合适的市场</b></blockquote></p><p> As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p><p><blockquote>如上所述，世界上最大的汽车市场具有巨大的增长潜力。问题是，将会有很多公司寻求资本化。<b>特斯拉</b>（纳斯达克：TSLA）在上海建立第二家制造工厂是有原因的。尽管蔚来和小鹏汽车可能是中国最知名的电动汽车制造商，但它们总共交付了131,000辆纯电动汽车的一半多一点。<b>比亚迪</b>（场外交易代码：比亚迪）2020年售出。</blockquote></p><p> NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p><p><blockquote>蔚来在2020年交付了近44,000辆汽车，而小鹏汽车的销量比2019年增加了一倍多，达到27,041辆。两家公司最近都推出了轿车车型，都希望这些车型能够成为未来销售增长的重要推动力。</blockquote></p><p> XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p><p><blockquote>自2020年初推出以来，小鹏汽车的P7运动型轿车累计交付量已超过20,000辆，超越G3紧凑型SUV成为该公司最受欢迎的汽车。这标志着中国电动汽车初创企业交付20,000辆汽车的最快速度。</blockquote></p><p> NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p><p><blockquote>蔚来今年早些时候推出了新款ET7豪华轿车。ET7将于明年初上市，具有一些复杂的功能。时尚的外观包括自动驾驶传感器、“水晶般的心跳”尾灯、全玻璃车顶和数字进入系统，该系统可以延伸齐平把手，并在驾驶员靠近时自动释放车门的“电子锁”。</blockquote></p><p> <b>Priced for perfection</b></p><p><blockquote><b>完美定价</b></blockquote></p><p> The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p><p><blockquote>强劲的销售增长以及中国电动汽车的巨大潜力已经让投资者涌入这些股票。但在蔚来和小鹏汽车的股价去年飙升后，这些股票分别较2021年1月的高点下跌了27%和38%，现在是看看哪一个可能更好买入的好时机。</blockquote></p><p> Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p><p><blockquote>两家公司都尚未盈利，因此衡量估值的一种方法是使用销售额而不是收益。市销率（P/S）都非常高，但销售额预计将快速增长，这是比较两家公司的相关指标。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的蔚来市值数据</span></p></blockquote></p><p> Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p><p><blockquote>尽管蔚来的市值较高，但以市盈率衡量，它的成本低于小鹏汽车。蔚来还通过其电池更换计划对市场采取了独特的方法，允许客户通过更快的电池更换来“充电”。该公司表示，其自动电池交换站只需三分钟即可更换充满电的电池。</blockquote></p><p> <b>Looking ahead</b></p><p><blockquote><b>展望未来</b></blockquote></p><p> NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p><p><blockquote>蔚来凭借ET7进军豪华轿车领域可能有助于将该公司推向一个新的水平。2020年毛利率、毛利润和经营现金流均为正，表明盈利之路在望。</blockquote></p><p> Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p><p><blockquote>两家公司都希望有足够的资本来资助计划的增长工作。截至2020年12月31日，蔚来资产负债表上的现金和现金等价物、限制性现金和短期投资为65亿美元，小鹏汽车约为54亿美元。两家公司可以通过在香港联交所上市来筹集更多资金，据报道，两家公司都在考虑上市。</blockquote></p><p> For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p><p><blockquote>对于只想选择一家公司来参与中国电动汽车增长的投资者来说，蔚来似乎是这两家公司中更好的选择。任何投资仍然属于投资组合的投机部分，有可能出现很大的波动。但对于那些能够承受这一点并进行适当投资的人来说，最近股价的下跌使蔚来目前比小鹏汽车更值得买入。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Buy: NIO vs. XPeng Motors<blockquote>更值得购买：蔚来与小鹏汽车</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Buy: NIO vs. XPeng Motors<blockquote>更值得购买：蔚来与小鹏汽车</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-03-15 09:22</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p><p><blockquote>即使在股价低迷之后，这两家中国电动汽车制造商的估值也很高。</blockquote></p><p> Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p><p><blockquote>电动汽车(EV)制造商的股票在2020年加速上涨。众所周知，中国电动汽车股票是最受欢迎的股票之一，因为这个全球最大的汽车市场继续向交通领域的电气化迈进。</blockquote></p><p> EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p><p><blockquote>2020年，中国电动汽车销量超过100万辆，政府希望到2025年将这一数字增长到500万辆。据研究机构BloombergNEF称，到2030年，这一数字可能达到1000万，到2040年接近2000万。两家希望利用这一扩张的电动汽车制造商是<b>蔚来</b>（纽约证券交易所代码：蔚来）和<b>小鹏</b>（纽约证券交易所代码：XPEV）。投资者可能想知道哪一个更好，尤其是在该行业股价出现调整之后。</blockquote></p><p> <b>The right market</b></p><p><blockquote><b>合适的市场</b></blockquote></p><p> As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p><p><blockquote>如上所述，世界上最大的汽车市场具有巨大的增长潜力。问题是，将会有很多公司寻求资本化。<b>特斯拉</b>（纳斯达克：TSLA）在上海建立第二家制造工厂是有原因的。尽管蔚来和小鹏汽车可能是中国最知名的电动汽车制造商，但它们总共交付了131,000辆纯电动汽车的一半多一点。<b>比亚迪</b>（场外交易代码：比亚迪）2020年售出。</blockquote></p><p> NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p><p><blockquote>蔚来在2020年交付了近44,000辆汽车，而小鹏汽车的销量比2019年增加了一倍多，达到27,041辆。两家公司最近都推出了轿车车型，都希望这些车型能够成为未来销售增长的重要推动力。</blockquote></p><p> XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p><p><blockquote>自2020年初推出以来，小鹏汽车的P7运动型轿车累计交付量已超过20,000辆，超越G3紧凑型SUV成为该公司最受欢迎的汽车。这标志着中国电动汽车初创企业交付20,000辆汽车的最快速度。</blockquote></p><p> NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p><p><blockquote>蔚来今年早些时候推出了新款ET7豪华轿车。ET7将于明年初上市，具有一些复杂的功能。时尚的外观包括自动驾驶传感器、“水晶般的心跳”尾灯、全玻璃车顶和数字进入系统，该系统可以延伸齐平把手，并在驾驶员靠近时自动释放车门的“电子锁”。</blockquote></p><p> <b>Priced for perfection</b></p><p><blockquote><b>完美定价</b></blockquote></p><p> The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p><p><blockquote>强劲的销售增长以及中国电动汽车的巨大潜力已经让投资者涌入这些股票。但在蔚来和小鹏汽车的股价去年飙升后，这些股票分别较2021年1月的高点下跌了27%和38%，现在是看看哪一个可能更好买入的好时机。</blockquote></p><p> Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p><p><blockquote>两家公司都尚未盈利，因此衡量估值的一种方法是使用销售额而不是收益。市销率（P/S）都非常高，但销售额预计将快速增长，这是比较两家公司的相关指标。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的蔚来市值数据</span></p></blockquote></p><p> Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p><p><blockquote>尽管蔚来的市值较高，但以市盈率衡量，它的成本低于小鹏汽车。蔚来还通过其电池更换计划对市场采取了独特的方法，允许客户通过更快的电池更换来“充电”。该公司表示，其自动电池交换站只需三分钟即可更换充满电的电池。</blockquote></p><p> <b>Looking ahead</b></p><p><blockquote><b>展望未来</b></blockquote></p><p> NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p><p><blockquote>蔚来凭借ET7进军豪华轿车领域可能有助于将该公司推向一个新的水平。2020年毛利率、毛利润和经营现金流均为正，表明盈利之路在望。</blockquote></p><p> Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p><p><blockquote>两家公司都希望有足够的资本来资助计划的增长工作。截至2020年12月31日，蔚来资产负债表上的现金和现金等价物、限制性现金和短期投资为65亿美元，小鹏汽车约为54亿美元。两家公司可以通过在香港联交所上市来筹集更多资金，据报道，两家公司都在考虑上市。</blockquote></p><p> For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p><p><blockquote>对于只想选择一家公司来参与中国电动汽车增长的投资者来说，蔚来似乎是这两家公司中更好的选择。任何投资仍然属于投资组合的投机部分，有可能出现很大的波动。但对于那些能够承受这一点并进行适当投资的人来说，最近股价的下跌使蔚来目前比小鹏汽车更值得买入。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","NIO":"蔚来"},"source_url":"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161179297","content_text":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.\nStocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.\nEV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are NIO (NYSE:NIO) and XPeng (NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.\nThe right market\nAs noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.Tesla (NASDAQ:TSLA) built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that BYD (OTC:BYDDY) sold in 2020.\nNIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.\nXPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.\nNIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.\nPriced for perfection\nThe strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.\nNeither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The price-to-sales ratios (P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.\nNIO MARKET CAP DATA BY YCHARTS\nThough NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.\nLooking ahead\nNIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.\nBoth companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.\nFor investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.","news_type":1,"symbols_score_info":{"XPEV":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":1373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":109695483,"gmtCreate":1619688398542,"gmtModify":1634210712908,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576882204250083","idStr":"3576882204250083"},"themes":[],"htmlText":"เซม","listText":"เซม","text":"เซม","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/109695483","repostId":"374290611","repostType":1,"repost":{"id":374290611,"gmtCreate":1619447027033,"gmtModify":1631888271015,"author":{"id":"3574652001822174","authorId":"3574652001822174","name":"DWP","avatar":"https://static.tigerbbs.com/cf842b9e680a5ecebea8472f4a157226","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574652001822174","idStr":"3574652001822174"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","listText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","text":"$HUMBL Inc.(HMBL)$bleeeeeeding 😪","images":[{"img":"https://static.tigerbbs.com/8b79a88da903c7e0e8036cad05a222bf","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374290611","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1721,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364834174,"gmtCreate":1614832110998,"gmtModify":1703481713436,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576882204250083","idStr":"3576882204250083"},"themes":[],"htmlText":"👌🏻","listText":"👌🏻","text":"👌🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/364834174","repostId":"1172714394","repostType":4,"repost":{"id":"1172714394","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614783206,"share":"https://www.laohu8.com/m/news/1172714394?lang=zh_CN&edition=full","pubTime":"2021-03-03 22:53","market":"us","language":"en","title":"Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴Bharat Biotech COVID-19候选疫苗显示出81%的功效后，Ocugen股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172714394","media":"老虎资讯综合","summary":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-develo","content":"<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>飙升41.0%，此前该生物制药公司表示，其共同开发合作伙伴Bharat Biotech发布了对其COVID-19候选疫苗科瓦克辛的3期试验的中期分析，该试验显示疗效为81%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat在印度的3期试验招募了25800名年龄在18至91岁的参与者，首次中期分析基于43例病例。对安全性数据库的审查显示，严重、严重和医疗护理的不良事件发生率较低，并且在疫苗组和安慰剂组之间保持平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen首席执行官Shankar Musunuri表示：“这些结果部分表明针对快速出现的英国变种具有显着的免疫原性，这代表着朝着概述EUA和美国批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于整个病毒体的候选疫苗，旨在满足我们国家针对COVID-19的疫苗库中尚未满足的重大需求。”Ocugen的股价在过去三个月内飙升了3,071.5%，而iShares纳斯达克生物技术ETF上涨了6.8%，标普500上涨了5.6%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴Bharat Biotech COVID-19候选疫苗显示出81%的功效后，Ocugen股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy<blockquote>合作伙伴Bharat Biotech COVID-19候选疫苗显示出81%的功效后，Ocugen股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-03 22:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><blockquote>（3月3日）<a href=\"https://laohu8.com/S/OCGN\">组织发生学</a>飙升41.0%，此前该生物制药公司表示，其共同开发合作伙伴Bharat Biotech发布了对其COVID-19候选疫苗科瓦克辛的3期试验的中期分析，该试验显示疗效为81%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p><blockquote>Bharat在印度的3期试验招募了25800名年龄在18至91岁的参与者，首次中期分析基于43例病例。对安全性数据库的审查显示，严重、严重和医疗护理的不良事件发生率较低，并且在疫苗组和安慰剂组之间保持平衡。</blockquote></p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p><blockquote>Ocugen首席执行官Shankar Musunuri表示：“这些结果部分表明针对快速出现的英国变种具有显着的免疫原性，这代表着朝着概述EUA和美国批准的监管途径又迈出了一步。”</blockquote></p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p><p><blockquote>“科瓦克辛是一种基于整个病毒体的候选疫苗，旨在满足我们国家针对COVID-19的疫苗库中尚未满足的重大需求。”Ocugen的股价在过去三个月内飙升了3,071.5%，而iShares纳斯达克生物技术ETF上涨了6.8%，标普500上涨了5.6%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172714394","content_text":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}